2023 World Conference on Lung Cancer (Posters)-EP12.01. Benefits of Afatinib and Osimertinib in a Patient with Lung Adenocarcinoma Harboring EGFR19Del/T790M/G724S Mutation

EP12.01. Benefits of Afatinib and Osimertinib in a Patient with Lung Adenocarcinoma Harboring EGFR19Del/T790M/G724S Mutation - PDF(Abstract)

Back to course

Pdf Summary

This document presents a case report on the benefits of afatinib and osimertinib in a patient with lung adenocarcinoma having specific mutations in the epidermal growth factor receptor (EGFR) gene. The patient, a 63-year-old Chinese female non-smoker, initially responded well to gefitinib treatment for 30 months. However, when her disease progressed, a next-generation sequencing (NGS) test revealed the presence of EGFR G724S/T790M/19Del mutations. This combination of mutations can lead to resistance to EGFR tyrosine kinase inhibitors (TKIs). <br /><br />The patient was then switched to osimertinib, but after one month, her condition worsened. Therefore, a combination therapy of afatinib and osimertinib was initiated. After two months, the patient's respiratory symptoms improved, and after five months, a follow-up CT scan showed a significant reduction in the pulmonary mass. As of the cutoff date of April 10, 2023, the patient has continued to receive afatinib and osimertinib without any significant adverse reactions.<br /><br />The emergence of the EGFR G724S mutation can limit the effectiveness of first- or third-generation EGFR TKIs in NSCLC patients with EGFR19Del mutations. However, the study demonstrates that afatinib overcomes EGFRG724S-mediated TKIs resistance, both in vitro and in vivo. The combination of afatinib and osimertinib could be a new therapeutic option for patients with lung adenocarcinoma harboring EGFRG724S/T790M/19Del mutations.<br /><br />This case report highlights the potential for targeted therapies, specifically afatinib and osimertinib, in improving the treatment outcomes for patients with lung adenocarcinoma and specific EGFR mutations. Further research and clinical trials are needed to validate the efficacy and safety of this combination therapy approach.

Asset Subtitle

Xin Lyu

Meta Tag

Speaker Xin Lyu

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

afatinib

osimertinib

lung adenocarcinoma

EGFR gene mutations

gefitinib

next-generation sequencing

EGFR tyrosine kinase inhibitors

combination therapy

EGFR G724S mutation

targeted therapies